A study evaluating correlation between tumor infiltrating lymphocytes and clinical outcomes in advanced non small cell lung cancer patients treated with Nivolumab.

Trial Profile

A study evaluating correlation between tumor infiltrating lymphocytes and clinical outcomes in advanced non small cell lung cancer patients treated with Nivolumab.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2017 New trial record
    • 12 Sep 2017 Primary end point (correlate TIL density with progression free survival (PFS)) has been met as per the results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top